Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

References

• VothDEBallardJDClostridium difficile toxins: mechanism of action and role in diseaseClin Microbiol Rev200518224726315831824
   PubMed Web of Science ®Google Scholar
• SammonsJSToltzisPZaoutisTEClostridium difficile infection in childrenJAMA Pediatr2013167656757323460123
   PubMed Web of Science ®Google Scholar
• JangiSLamontJTAsymptomatic colonization by Clostridium difficile in infants: implications for disease in later lifeJ Pediatr Gastroenterol Nutr20105112720512057
   PubMed Web of Science ®Google Scholar
• LefflerDALamontJTClostridium difficile infectionN Engl J Med2015372161539154825875259
   PubMed Web of Science ®Google Scholar
• OwensRCJrDonskeyCJGaynesRPLooVGMutoCAAntimicrobial-associated risk factors for Clostridium difficile infectionClin Infect Dis200846suppl 1S19S3118177218
   PubMed Web of Science ®Google Scholar
• NicholsonMRThomsenIPSlaughterJCCreechCBEdwardsKMNovel risk factors for recurrent Clostridium difficile infection in childrenJ Pediatr Gastroenterol Nutr2015601182225199038
   PubMed Web of Science ®Google Scholar
• KimJShakleeJFSmathersSRisk factors and outcomes associated with severe Clostridium difficile infection in childrenPediatr Infect Dis J201231213413822031485
   PubMed Web of Science ®Google Scholar
• NylundCMEideMGormanGHAssociation of Clostridium difficile infections with acid suppression medications in childrenJ Pediatr2014165597998425112692
   PubMed Web of Science ®Google Scholar
• SandoraTJFungMFlahertyKEpidemiology and risk factors for Clostridium difficile infection in childrenPediatr Infect Dis J201130758058421233782
   PubMed Web of Science ®Google Scholar
• SchwabEMWilkesJKorgenskiKRisk factors for recurrent Clostridium difficile infection in pediatric inpatients. American Academy of Pediatrics/Section on hospital medicineHosp Pediatr20166633934427146969
   PubMedGoogle Scholar
• Lo VecchioALancellaLTagliabueCClostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence countryE J Clin Microbiol Infect Dis2017361177185
   Web of Science ®Google Scholar
• BoltonRPCulshawMAFaecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficileGut19862710116911723781329
   PubMed Web of Science ®Google Scholar
• ToltzisPKimJDulMZoltanskiJSmathersSZaoutisTPresence of the epidemic North American pulsed field type 1 Clostridium difficile strain in hospitalized childrenJ Pediatr2009154460760819324222
   PubMed Web of Science ®Google Scholar
• BryantKMcDonaldLCClostridium difficile infections in childrenPediatr Infect Dis J200928214514619174687
   PubMed Web of Science ®Google Scholar
• SeeIMuYCohenJNAP1 strain type predicts outcomes from Clostridium difficile infectionClin Infect Dis201458101394140024604900
   PubMed Web of Science ®Google Scholar
• BauerKAJohnstonJEWWenzlerEImpact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infectionAnaerobe2017481628645479
   PubMed Web of Science ®Google Scholar
• DebastSBBauerMPKuijperEJEuropean Society of Clinical Microbiology and Infectious DiseasesEuropean Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infectionClin Microbiol Infect201420suppl 2126
   PubMed Web of Science ®Google Scholar
• CohenSHGerdingDNJohnsonSSociety for Healthcare Epidemiology of America; Infectious Diseases Society of AmericaClinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)Infect Control Hosp Epidemiol201031543145520307191
   PubMed Web of Science ®Google Scholar
• SpivackJGEppesSCKleinJDClostridium difficile-associated diarrhea in a pediatric hospitalClin Pediatr (Phila)200342434735212800729
   PubMed Web of Science ®Google Scholar
• PaiSAliyuSHEnochDAKarasJAFive years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and managementPLoS One2012712e5172823300561
   PubMed Web of Science ®Google Scholar
• KimJSmathersSAPrasadPLeckermanKHCoffinSZaoutisTEpidemiological features of Clostridium difficile-associated disease among inpatients at children’s hospitals in the United States, 2001–2006Pediatrics200812261266127019047244
   PubMed Web of Science ®Google Scholar
• NylundCMGoudieAGarzaJMFairbrotherGCohenMBClostridium difficile infection in hospitalized children in the United StatesArch Pediatr Adolesc Med2011165545145721199971
   PubMedGoogle Scholar
• ZilberbergMDTillotsonGSMcDonaldCClostridium difficile infections among hospitalized children, United States, 1997–2006Emerg Infect Dis201016460460920350373
   PubMed Web of Science ®Google Scholar
• DubberkeERGerdingDNClassenDStrategies to prevent Clostridium difficile infections in acute care hospitalsInfect Control Hosp Epidemiol200829suppl 1S81S9218840091
   PubMed Web of Science ®Google Scholar
• SchutzeGEWilloughbyRECommittee on Infectious Diseases; American Academy of PediatricsClostridium difficile infection in infants and childrenPediatrics2013131119620023277317
   PubMed Web of Science ®Google Scholar
• WenischCParschalkBHasenhündlMHirschlAMGraningerWComparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrheaClin Infect Dis19962258138188722937
   PubMed Web of Science ®Google Scholar
• TeasleyDGGerdingDNOlsonMMProspective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitisLancet198328358104310466138597
   PubMed Web of Science ®Google Scholar
• ZarFABakkanagariSRMoorthiKMDavisMBA comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severityClin Infect Dis200745330230717599306
   PubMed Web of Science ®Google Scholar
• ShetlerKNieuwenhuisRWrenSMTriadafilopoulosGDecompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitisSurg Endosc200115765365911591962
   PubMed Web of Science ®Google Scholar
• RokasKEJohnsonJWBeardsleyJROhlCALutherVPWilliamsonJCThe addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infectionClin Infect Dis201561693494126024909
   PubMed Web of Science ®Google Scholar
• CrewsJKaplanSLTorchiaMMPostTW webpage on the InternetClostridium diffficile Infection in Children: Treatment and Outcomes Available from: https://www.uptodate.com/contents/clostridium-difficile-infection-in-children-treatment-and-outcomeAccessed August 29, 2017
   Google Scholar
• McFarlandLVElmerGWSurawiczCMBreaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile diseaseAm J Gastroenterol20029771769177512135033
   PubMed Web of Science ®Google Scholar
• GuarinoAAshkenaziSGendrelDEuropean Society for Pediatric Gastroenterology, Hepatology, and NutritionEuropean Society for Pediatric Infectious DiseasesEuropean Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014J Pediatr Gastroenterol Nutr201459113215224739189
   PubMed Web of Science ®Google Scholar
• Metronidazole [prescribing Information]Parsippany, NJWatson Labs2006
   Google Scholar
• LampKCFreemanCDKlutmanNELacyMKPharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobialsClin Pharmacokinet199936535337310384859
   PubMed Web of Science ®Google Scholar
• Vancomycin Hydrochloride [prescribing information]Lake Forest, ILAkron, Inc2013
   Google Scholar
• BhansaliSGMullaneKTingLSPharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infectionsAntimicrob Agents Chemother20155931441144525534724
   PubMed Web of Science ®Google Scholar
• Dificid (fidaxomicin) [prescribing information]Whitehouse Station, NJMerck2015
   Google Scholar
• ZhanelGGWalktyAJKarlowskyJAFidaxomicin: A novel agent for the treatment of Clostridium difficile infectionCan J Infect Dis Med Microbiol201526630531226744587
   PubMed Web of Science ®Google Scholar
• SearsPKaplanSLMichaelsMFlanaganSO’gormanM webpage on the InternetSafety and Pharmacokinetic Study of Fidaxomicin in Children with Clostridium difficile-Associated DiarrheaPhiladelphia, PAID Week2014 Available from: https://idsa.confex.com/idsa/2014/webprogram/Paper48416.htmlAccessed October, 2014
   Google Scholar
• Optimer Pharmaceuticals LLCSafety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) ClinicalTrials.gov [Internet]Bethesda, MDUS National Library of Medicine2000 Available from: https://clinicaltrials.gov/show/NCT1591863. NLM Identifier: NCT1591863Accessed April 8, 2017
   Google Scholar
• ShueYKSearsPSShangleSSafety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral dosesAntimicrob Agents Chemother20085241391139518268081
   PubMed Web of Science ®Google Scholar
• LiRLuLLinYWangMLiuXEfficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysisPLoS One20151010e013725226444424
   PubMed Web of Science ®Google Scholar
• LouieTMillerMDonskeyCMullaneKGoldsteinEJClinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infectionAntimicrob Agents Chemother200953122323818955525
   PubMed Web of Science ®Google Scholar
• FeketyRSilvaJKauffmanCBuggyBDeeryHGTreatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimensAm J Med19898611519
   PubMed Web of Science ®Google Scholar
• SmeltzerSHassounASuccessful use of fidaxomicin in recurrent Clostridium difficile infection in a childJ Antimicrob Chemother20136871688168923463209
   PubMed Web of Science ®Google Scholar
• LouieTJMillerMAMullaneKMOPT-80-003 Clinical Study GroupFidaxomicin versus vancomycin for Clostridium difficile infectionN Engl J Med2011364542243121288078
   PubMed Web of Science ®Google Scholar
• ZhnagSPalazuelos-MunozSBalsellsEMNairHChitAKyawMHCost of hospital management of Clostridium difficile infection in United States – a meta-analysis and modeling studyBMC Infect Dis201616144746527562241
   PubMed Web of Science ®Google Scholar
• KuijperEJCoignardBTüllPEmergence of Clostridium difficile-associated disease in North America and Europe. ESCMID Study Group for Clostridium difficile (ESGCD) and EU Member States and the European Centre for Disease Prevention and Control (ECDC)Clin Microbiol Infect200612s6218
   Web of Science ®Google Scholar
• AsensioADi BellaSLo VecchioAThe impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort studyInt J Infect Dis201536313826003403
   PubMed Web of Science ®Google Scholar
• RED BOOK Online [database on the Internet]Truven Health Analytics Available from: http://www.micromedexsolutions.comAccessed August 29, 2017
   Google Scholar
• ThomasKLHolmesKJacksonBRA cost comparison of metronidazole and vancomycin in the treatment of Clostridium difficile associated diarrheaAm J Gastroenterol2007102suppl 2S268
   Web of Science ®Google Scholar
• PerrasCTsakonasENdegwaSVancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic AnalysesOttawaCanadian Agency for Drugs and Technologies in Health2011156 Technology Report; No. 136
   Google Scholar
• GallagherJCReillyJPNavalkeleBDownhamGHaynesKTrivediMClinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infectionAntimicrob Agents Chemother201559117007701026324268
   PubMed Web of Science ®Google Scholar
• NathwaniDCornelyOAVan EngenAKOdufowora-SitaORetsaPOdeyemiIACost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infectionJ Antimicrob Chemother201469112901291225096079
   PubMed Web of Science ®Google Scholar
• KonijetiGGSaukJShrimeMGGuptaMAnanthakrishnanANCost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysisClin Infect Dis201458111507151424692533
   PubMed Web of Science ®Google Scholar
• SurawiczCMBrandtLJBinionDGGuidelines for diagnosis, treatment, and prevention of Clostridium difficile infectionsAm J Gastroenterol2013108447849823439232
   PubMed Web of Science ®Google Scholar
• Astellas Pharma IncA study to investigate the safety and efficacy of fidaxomicin (oral suspension or tablets) and vancomycin (oral liquid or capsules) in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) (SUNSHINE) ClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine, US2000 Available from: https://clinicaltrials.gov/show/NCT2218372. NLM Identifier: NCT2218372Accessed August 29, 2017
   Google Scholar
• Merck Sharp & Dohme CorpBezlotoxumab (MK-6072) versus placebo in children with Clostridium difficile infection (MODIFY III) In ClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine, US2000 Available from: https://clinicaltrials.gov/show/NCT3182907. NLM Identifier: NCT3182907Accessed August 29, 2017
   Google Scholar
• WilcoxMHGerdingDNProxtonIRMODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrently Clostridium difficile infectionN Engl J Med2017376430531728121498
   PubMed Web of Science ®Google Scholar